Process and methods
7 Review and update
Every evidence summary includes the date of publication and a link to the British national formulary, summary of product characteristics, and NICE website with a reminder to consult these sources for up-to-date information on the topic. The need to withdraw an evidence summary is considered by the MTP on an ongoing basis as part of its current awareness activities (see Medicines and Prescribing Alerts on the NICE website). In addition, guidance information services will conduct an annual search for licence changes that relate to unlicensed or off-label use of medicines. Examples of circumstances when an evidence summary may be withdrawn include:
If a NICE technology appraisal or guideline that relates to the medicine and indication reviewed in the evidence summary is published.
A product obtains a licence for the indication that the evidence summary has reviewed where previously this was an unlicensed or off-label use. The medicine will then be considered as a potential topic for NICE technology appraisal guidance in line with the NICE topic selection process.